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Xuefu Zhuyu decoction, a classic prescription in traditional Chinese medicine, has been
widely used in the clinical treatment of cardiovascular and cerebrovascular diseases. In
order to profile the chemical material basis of this formula, an ultra-performance liquid
chromatography (UPLC) coupled with quadrupole time-of-flight mass spectrometry (Q/TOF
MS) method has been established for rapid separation and structural characterization of
compounds in the decoction. As a result, 103 compounds including phenolic acids, sper-
midines, C-glycosyl quinochalcones, terpenoids, flavonoids, saponins, and others were
detected; 35 of them were unambiguously identified, and 68 were tentatively characterized
by comparing the retention time, MS data, characteristic MS fragmentation pattern and
retrieving the literature. In conclusion, the UPLC coupled with quadrupole time-of-flight
mass spectrometry method developed in this work is an efficient approach to perform
chemical material basis studies of traditional Chinese medicine formulae.
Copyright © 2015, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.
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Cardiovascular and cerebrovascular diseases are common
diseases of the elderly that have seriously threatened
human health in recent years. Even when the most
advanced and comprehensive treatment was applied, more
than 50% of the survivors from cardiovascular and cerebro-
vascular incidents were still unable to provide for them-
selves completely. Every year around the world, as many as
15 million people die of cardiovascular and cerebrovascular
diseases. They have become one of the primary causes of
human death.
The traditional Chinese medicine formula Xuefu Zhuyu
decoction (XFZYD) was first recorded in Yilin Gaicuo (Correc-
tion of Medical Errors, 1850) by Qingren Wang (1768e1831) [1].
The herbal combination is regarded as a modification of two
famous classic prescriptions, Taohong Siwu decoction (Peach
Seed and Safflower Decoction of Four Ingredients) and Sinisan
(Powder for Regulating Liver and Spleen) [2], which comprises
11 herbs: Semen prunus (Taoren) 12 g, Radix Angelicae sinensis
(Danggui) 9 g, Rhizoma chuanxiong (Chuanxiong) 4.5 g, Flos
carthami (Honghua) 9 g, Radix Paeoniae rubra (Chishao) 6 g,
Radix rehmanniae (Dihuang) 9 g, Fructus aurantii (Zhiqiao) 6 g,
Radix Bupleuri (Chaihu) 3 g, Radix platycodonis (Jiegeng) 4.5 g,
Radix Achyranthis bidentatae (Niuxi) 9 g, and Radix and Rhi-
zoma glycyrrhizae (Gancao) 6 g [3,4]. XFZYD has been
demonstrated to show definite protection in the cardiovas-
cular and cerebrovascular system, and modern pharmaco-
logical studies have elucidated the protective mechanisms
[5,6]. XYZFD could induce endothelial progenitor cell angio-
genesis, hasten tube formation [7], and regulate blood lipid
[8,9]. Satisfactory clinical efficiency has been achieved for
cardiovascular and cerebrovascular diseases [10] such as
atherosclerosis, hypertension, hyperlipidemia, thromboem-
bolism, and angina pectoris.
It is well known that the therapeutic effects of herbal
medicine are due to the synergistic contribution of multiple
constituents [11]. Since XFZYD has centuries of clinical use
and reliable curative efficacy, developing a feasible and
rapid analytical method for characterizing the constituents
in the decoction is valuable and vital to ensuring its reli-
ability and safety in clinical therapy. Many researchers
have made significant contributions to the studies of sub-
stance foundation in XFZYD. Zhang et al [12] and Liu et al
[13] used high-performance liquid chromatographyemass
spectrometry (HPLC-MS) methods to identify anti-
atherogenic constituents of the decoction. Gao et al [14]
introduced an HPLCeevaporative light scattering detector
method to quantify chemical constituents in the XFZY
capsule. In our previous study, an ultra-performance liquid
chromatography (UPLC) coupled with diode array detector
tandem MS method was undertaken to perform quantita-
tive and qualitative analysis of the constituents in XFZYD
products [15].
In order to deeply unveil the chemical compositions of
XFZYD, a UPLC coupled with quadrupole time-of-flight (Q/
TOF) MSmethod was introduced and established in this work.
A total of 103 constituents were unambiguously identified or
tentatively characterized. This also provides a valuablereference for further research and development of this for-
mula and its related medicinal products.2. Methods
2.1. Reagents and materials
HPLC grade acetonitrile and methanol were purchased from
Merck (Merck, Darmstadt, Germany) and Sigma (Sigma-
eAldrich, St Louis, MO, USA), respectively. Formic acid and
dimethyl sulfoxide were obtained from Meridian Medical
Technologies (Columbia, MD, USA). Water used in the exper-
iment was purified by a Milli-Q water purification system
(Millipore, Billerica, MI, USA).
Reference compounds (gallic acid, protocatechuic acid, p-
hydroxybenzoic acid, chlorogenic acid, caffeic acid, hydrox-
ysafflor yellow A, amygdalin, albiflorin, paeoniflorin, p-
hydroxycinnamic acid, ferulic acid, schaftoside, 6-hydroxy
kaempferol-3-O-glucoside, liquiritin, rutin, isoquercitrin, ver-
bascoside, astragalin, narirutin, b-ecdysterone, naringin,
rhoifolin, hesperidin, neohesperidin, liquiritigenin, nar-
ingenin, kaempferol, platycodin D, isoliquiritigenin, for-
mononetin, ginsenoside-Ro, 18b-glycyrrhizic acid, chikusetsu
saponin Iva, nobiletin, and saikosaponin A) were obtained
from the National Institute for Food and Drug Control (Beijing,
China), Tianjin ZhongXin Pharmaceutical Group Co., Ltd.
(Tianjin, China), and Top High Bio Technology Co., Ltd.
(Nanjing, China). The purities of standards were >98%.2.2. Preparation of standard solutions
Reference compounds were accurately weighed and directly
prepared in methanol and dimethyl sulfoxide as individual
standard stock solutions; following this mixed standard stock
solutions containing all 35 standards were prepared. A work-
ing standard solution was prepared by diluting the mixed
stock solution with water (v/v, 1:3) to obtain a suitable
concentration.2.3. Plant material and sample preparation
The plant materials (Taoren, Danggui, Chuanxiong, Honghua,
Chishao, Dihuang, Zhiqiao, Chaihu, Jiegeng, Niuxi, and Gan-
cao) were purchased fromAnguo (Hebei, China) and identified
by Professor Tianxiang Li. All herbs were deposited in Tianjin
State Key Laboratory of Modern Chinese Medicine.
According to the traditional formula, 11 plant materials
(total weight of 78 g) were mixed and immersed in 600 mL
deionized water for 1 hour at room temperature, and then
refluxed for 2 hours twice. After filtration and concentration,
aqueous extract was dried at 45C in an oven under vacuum to
give 30 g original extract powder. The yield of preparation was
38.5%. A 10 mL aliquot of methanol was added to 0.4 g of
extract powder and sonicated for 30min at room temperature.
The solution was diluted with deionized water (v/v, 1:1) and
then centrifuged at 17,968 g for 10 min. Finally, the superna-
tant was transferred to autosampler vials for UPLC-Q/TOF MS
analysis.
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Analysis was performed on a Waters ACQUITY UPLC system
(Binary Solvent Manager, Sample Manger and thermostati-
cally controlled column compartment; Waters Co., Parsip-
pany, NJ, USA) coupled with Waters SYNAPT G2 high
definition mass spectrometer (HDMS) with a LockSpray and
an electrospray ionization (ESI) interface. The system was
controlled under MassLynx V4.1 software (Waters).
Gradient elution was performed on an ACQUITY UPLC BEH
C18 column (2.1  100 mm, 1.7 mm; Waters) at 50C. The
mobile phase was composed of 0.1% formic acid aqueous
solution (A) and acetonitrile (B). The gradient program applied
was as follows: 0e6.5 min, 3e11% B; 6.5e15 min, 11e20% B;
15e20 min, 20e36% B; 20e27 min, 36e48% B; 27e30 min,
48e55% B; 30e33 min, 55e74% B, and 33e35 min, 74e90%
B. The flow rate was 0.3 mL/min and injection volume was
5 mL.
The analysis of mass spectra was performed in both posi-
tive and negative modes. And, the spectra were recorded in
the range of m/z 100e1500 Da for full scan. The optimal MS
parameters were: capillary voltage, 2.5 kV (negative ion
mode), 3.0 kV (positive ion mode); capillary temperature,
120C; desolvation temperature, 400C; desolvation gas (N2)
flow, 700 L/h; cone gas (N2) flow, 50 L/h; collision gas (Ar) flow
rate, 0.20 mL/min; the MS and MS/MS acquisition rate was set
at 0.2 s in centroid mode. Mass accuracy was maintained
using a LockSpray with leucineeenkephalin for positive ion
mode [(MþH)þ ¼ 556.2771] and negative ion mode
[(MeH)e ¼ 554.2615] at a concentration of 200 pg/mL.2.5. Data processing
MS andMS/MS data obtained from the robust UPLC-Q/TOFMS
were performed using the aforementioned protocol. The
chemical profiling study was based on retention time, precise
molecular mass, isotopic pattern, MS/MS data and MS frag-
mentation behavior. The mass accuracy of MS and MS/MS
data should be < 10.0 ppm.3. Results and Discussion
3.1. UPLC-MS characterization of chemical constituents
from XFZYD
The representative base peak intensity chromatograms of
XFZYD sample are presented in Fig. 1A and 1C corresponding
to negative and positive ion mode, respectively. A total of 103
compounds (Fig. S1) including 7 phenolic acids, 4 spermidines,
7 terpenoids, 52 flavonoids, 29 saponins, and 4 others were
characterized. Among them, 35 constituents were unambig-
uously identified by comparing retention time, MS, and MS/
MS data with the base peak intensity chromatograms of
authentic compounds (shown in Fig. 1B and 1D). A further 68
compounds were tentatively characterized by comparing ac-
curate mass of quasimolecular and product ions, character-
istic fragmentation patterns and related botanical biogenesis
with the literature.3.2. Fragmentation patterns study of XFZYD
The mass error for quasimolecular and product ions of all
compounds identified by UPLC-Q/TOF MS was within ±
10 ppm. The exact identification of each group of components
is outlined below.
3.3. Characterization of phenolic acids
Compounds P1, P2, P3, P4, P5, P6, and P7 were unequivocally
identifiedas gallic acid, protocatechuic acid, p-hydroxybenzoic
acid, chlorogenic acid, caffeic acid, hydroxycinnamic acid, and
ferulic acid, respectively, by comparison with authentic com-
pounds. Due to low ionization efficiency in positive ion mode,
most phenolic acids were only presented in negative ionmode
except chlorogenic acid. Compounds P1, P2, P3, P5, and P6
showed characteristic neutral loss of CO2. Compound P4
exhibited ions at m/z 353.0858 [MeH]e and 377.0849 [MþNa]þ.
The fragment ionatm/z191.0533 [MeHeC9H6O3]
eand215.0596
[MþNa-C9H6O3]þ corresponded to the loss of caffeoyl residue.
Compound P7 produced a dominant deprotonated ion at m/z
193.0499 [MeH]ewith typical consecutive loss of CH3, CO, and
CO2. The fragment ions of P7 at m/z 178.0242 [MeHeCH3]
e,
149.0543 [MeHeCO2]
e, and 134.0350 [MeHeCO2eCH3]
e were
shown in the negative MS/MS spectrum.
3.4. Characterization of flavonoids
Flavonoids exist in both free aglycones and glycoside forms
which include several classes of compounds with similar
structure having a common C6eC3eC6 flavone skeleton [16].
The cleavage of aglycones in flavonoids can be divided into
two broad categories: one is the retro DielseAlder reaction for
C ring, the other is the loss of small molecular fragments such
as CO, CH2O, CO2 and C2H2O. The flavonoid glycosides have
many isomers with the same molecular weight but different
aglycones and sugars conjugating at multiple linkage posi-
tions. Flavonoid glycosides exist in two main glycosylation
modes: O-glycosylation formed by the linkage of a carbon-
eoxygen bond and C-glycosylation formed by the linkage of a
carbonecarbon bond. These two flavonoid glycosides exhibit
entirely different fragmentation behaviors. For the O-glyco-
side form, loss of sugar moiety is the characteristic fragmen-
tation behavior. For the C-glycoside form, the stable
carbonecarbon bond is resistant to cleavage, so cleavage of
the sugar moiety is the typical MS fragmentation pattern.
3.4.1. Characterization of O-glycosylation flavonoids
The structures of flavonoids were identified at both positive
and negative ion modes, and some structures were further
validated with standards. Compounds FN12 and FN17 were
identified as naringin and naringenin. These two com-
pounds showed typical retro DielseAlder reaction for C ring
in both positive and negative ion modes. In positive
ion spectra of compound FN12, the fragment ion at m/z
457.1137 [MþNaeC6H10O4]þ was observed, which was
attributed to the loss of rhamnose. While the ion at m/z
271.0578 [MeHeC12H20O9]
‒ in negative ion mode corre-
sponded to the neutral loss of neohesperidose, the aglycone
of compound FN12, compound FN17 showed fragment
Fig. 1 e Base peak intensity chromatograms of Xuefu Zhuyu decoction extracts (A) in negative ion mode and (C) in positive
ion mode, base peak intensity chromatograms of mixed standards (B) in negative ion mode and (D) in positive ion mode by
ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. C ¼ chalcone;
F ¼ flavone; FN ¼ flavanone; IF ¼ isoflavone; O ¼ others; OF ¼ other flavonoid; Q ¼ C-glycosyl quinochalcone; P ¼ phenolic
acid; S ¼ saponin; SP ¼ spermidine; T ¼ terpenoid.
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[MþHeC6H6O3eCO]þ in positive ion mode, which were
reasonably attributed to the loss of benzene-1,3,5-triol and
CO. The ions at m/z 177.0160 [MeHeC6H6O]
‒, 151.0011
[MeHeC8H8O]
‒, and 107.0118 [MeHeC8H8OeCO2]
‒ in nega-
tive ion mode corresponded to the loss of phenol, 4-
vinylphenol, and CO2.
3.4.2. Characterization of C-glycosylation flavonoids
Compound F2 was identified as schaftoside. In positive
ion mode, Compound F2 yielded a quasimolecular ion at m/z565.1557 [MþH]þ. The fragment ions at m/z 547.1499
[MþHeH2O]þ, 529.1407 [MþHe2H2O]þ, and 511.1284
[MþHe3H2O]þ were attributed to successive dehydration
at sugar alcohol; the ion atm/z 445.1608 [MþHeC4H8O4]þ corre-
sponded to sugar bond cleavage. In negative ion
mode, compound F2 produced a quasimolecular ion at m/z
563.1393 [MeH]‒. Subsequently, compound F2 yielded fragment




‒, and 353.0613 [MeHeC3
H6O3eC4H8O4]
‒: typical fragment ions (m/z 120, 90, and 60) for
cleavage of sugar bonds, which are presented in Fig. 2.
Fig. 2 e Fragmentation from glucose moieties of C-glycosyl
flavonoids.
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Flos carthami, which have the same quinochalcone skeleton
with a hydroxyl and C-glucosyl group at the 50-position [17].
C-glycosyl quinochalcones showed special fragmentation
of glucose and branched groups in both positive and negative
ion modes. These typical fragmentation pathways made
it easy to characterize C-glycosyl quinochalcones in a complex
sample. For example, compound Q1 showed characteristic
internal cleavage of glucose, such as the loss of H2O, CH2O,
C2H4O2, and C4H8O4. The fragmentation behaviors of
compounds Q2eQ4 mainly occurred at branched chains.
In positive ion spectra, compound Q4 yielded major frag-
ment ions at m/z 517.0958 [MþNaeC8H8O]þ, 473.1053
[MþNaeC9H8O3]þ, 353.0487 [MþNaeC9H8O3eC8H8O]þ, and
311.0524 [MþNaeC9H8O3eC8H8OeC2H2O]þ, which was
reasonably attributed to the loss of p-vinyl phenol, 3-(4-
hydorxyphenyl)acrylic acid, and ethynol at side chain. Com-
pounds Q2 and Q3were C-glycosyl quinochalcones containing
a nitrogen atom. Their fragmentations showed a special
cleavage at the CeC bond except for the characteristic cleav-
age at branched chain. Homolysis (radical cleavage) of the
CeC bond occurred, which yielded a glucose free radical. By
comparison with the reported compounds and MS informa-
tion, compounds Q1eQ4 were tentatively characterized as
hydroxysafflor yellow A, hydroxycartormin, cartormin or
isomer, and safflomin C or isomer.3.5. Characterization of saponins
In negative ion mode, triterpene saponins yielded a dominant
quasimolecular ion [MeH]‒ and typical fragment ions at m/z
351.0564 [glucuro-glucuronic acid-H]‒ and 193.0348 [glucur-
onic acid-H]‒, or continuously lose sugars. In positive ion
spectra, the characteristic MS fragmentation behavior of sa-
ponins is consecutive loss of sugars and H2O. In addition,
acetylated saponins often lose an acetyl group before the be-
haviors mentioned above. All these features were highly
characteristic for the identification of triterpene saponins.
Finally, a total of 29 triterpene saponins (Tables 1 and S1) were
identified in XFZYD and showed similar MS behavior [18]. For
example, ions at m/z 823.4116 [MþH]þ and 821.3956 [MeH]‒ of
compound S23 were found in positive and negative MS spec-
trum, respectively. The fragment ions at m/z 647.3810
[MþHeC6H8O6]þ and 453.3374 [MþHe2C6H8O6eH2O]þ were
produced directly from the precursor ion, corresponding
to the neutral loss of a glucuronic acid unit, a glucuro-
glucuronic acid unit, and H2O. In negative mode, the frag-
ment ions at m/z 351.0544 [MeHeC30H46O4]
‒ and 193.0343
[MeHeC30H46O4eC6H8O6]
‒ corresponded to [glucuro-
glucuronic acid-H]‒ and [glucuronic acid-H]‒, respectively.Based on the MS/MS data and retention time compared with a
reference compound, compound S23 was identified as
18b-glycyrrhizic acid.
3.6. Characterization of terpenoids
Monoterpene glycosides are the major bioactive constituents
in Radix Paeoniae Rubra. The chemical structure of their
aglycones is generally a cage-like pinane skeleton, and glucose
was the only hexose hitherto reported in monoterpene
glycosidesofpaeoniaspecies [19].Themonoterpeneglycosides
are usually esterified with an aromatic acid such as benzoic
acid, p-hydroxybenzoic acid, or gallic acid. A total of five
monoterpene glycosides were identified based on their mass
spectra. For example, compound T2 was observed in high
abundance and was confirmed as paeoniflorin by comparison
with a reference standard. In positive ion spectra, the quasi-
molecular ion [MþH]þ was too weak to be observed. Instead,
compound T2 yielded a prominent adduct ion at m/z 503.1525
[MþNa]þ. In negative mode, a fragment ion at m/z 449.1378
[MeHeCH2O]
‒was observed, whichwas reasonably attributed
to the loss of a HCHO (formaldehyde) and assigned as the 5ʹ-
hydroxymethyl radical of theglucose residue [20]. The ionatm/
z 327.1041 [MeHeCH2OeC7H6O2]
‒ originated from the loss of
HCHO and benzoic acid. The product ion at m/z 121.0276
[MeHeCH2OeC15H20O8]
‒ indicated the presence of a benzoyl
group. Compound T1, an isomer of paeoniflorin, was un-
equivocally identified as albiflorin by comparison
with reference standard. In positive ion mode, it showed a
dominant adduct ion at m/z 503.1540 [MþNa]þ. The fragment
ions at m/z 341.0930 [MþNaeC6H10O5]þ and 219.0615
[MþNaeC6H10O5eC7H6O2]þ probably originated from the suc-
cessive losses of a hexose residue and benzoic acid. The
negative ion spectrum showed adduct ion at m/z 525.1608
[MeHþHCOOH]‒. The product ion at m/z 121.0278
[MeHþHCOOHeHCOOHeC16H22O9]‒ indicated the presence of
a benzoyl group.CompoundT3andT4were inducedas galloyl-
paeoniflorin or isomer. The product ions at m/z 169.0145
[MeHeC23H26O10]
‒ and 169.0191 [MeHeC23H26O10]
‒ suggested
the presence of galloyl radical; the productions atm/z 313.0562
[MeHeC17H18O6]
‒ and m/z 313.0547 [MeHeC17H18O6]
‒ corre-
sponded to a [galloyl glucose residue-H]‒.
3.7. Miscellaneous
Four isomers of spermidines (SP1e4) were detected and
identified as N1,N5,N10-(E)-tri-p-coumaroylspermidine,
N1,N5,N10-(Z)-tri-p-coumaroylspermidine, safflospermidine
A, and safflospermidine B from F. carthami [21]. These four
spermidines exhibited the same fragmentation pathways. For
instance, compound SP1 yielded a quasimolecular ion at m/z
582.2606 [MeH]‒ in negative ion mode. The fragment ions at
m/z 462.2029 [MeHeC8H8O]
‒ and 342.1451 [MeHe2C8H8O]
‒
originated from the loss of 4-vinylphenol. In positive ion
mode, a quasimolecular ion at m/z 584.2761 [MþH]þ was
observed. The product ions at m/z 438.2390 [MþHeC9H6O2]þ,
420.2283 [MþHeC9H6O2eH2O]þ, and 275.1764
[MþHeC9H6O2eC9H9NO2]þ originated from the successive
losses of 4-(3-oxoallylidene)cyclohexa-2,5-dienone, H2O, and
3-(4-hydroxyphenyl)acrylamide.




















*P1 1 1.485 d d d 169.0134 169.0137 1.8 C7H6O5 Gallic acid
O1 2 2.255 166.0865 166.0868 1.8 164.0693 164.0712 5.5 C9H11NO2 Phenylalanine
*P2 3 2.563 d d d 153.0485 153.0488 2.0 C7H6O4 Protocatechuic acid
*P3 4 3.829 d d d 137.0236 137.0239 2.2 C7H6O3 p-Hydroxybenzoic acid
*P4 5 4.790 377.0847 377.0849 0.5 353.0858 353.0873 4.2 C16H18O9 Chlorogenic acid
*P5 6 5.121 d d d 179.0339 179.0344 2.8 C9H8O4 Caffeic acid
*Q1 7 5.267 635.1578 635.1588 1.6 611.1619 611.1612 1.1 C27H32O16 Hydroxysafflor yellow A
*O2 8 5.864 480.1482 480.1482 0.0 456.1495 456.1506 2.4 C20H27NO11 Amygdalin
FN1 9 7.116 473.1028 473.1060 6.8 449.1076 449.1084 1.8 C21H22O11 Neocarthamin
*P6 10 7.182 d d d 163.0391 163.0395 2.5 C9H8O3 p-Hydroxycinnamic acid
F1 11 7.472 595.1670 595.1663 1.2 593.1503 593.1506 0.5 C27H30O15 Vicenin-2
*T1 12 7.626 503.1540 503.1529 2.2 525.1608 525.1608 0.0 C23H28O11 Albiflorin
*T2 13 8.433 503.1525 503.1529 0.8 479.1541 479.1553 2.5 C23H28O11 Paeoniflorin
*P7 14 8.835 d d d 193.0499 193.0501 1.0 C10H10O4 Ferulic acid
*F2 15 8.835 565.1581 565.1557 4.2 563.1393 563.1401 1.4 C26H28O14 Schaftoside
FN2 16 9.290 765.2225 765.2218 0.9 741.2211 741.2242 4.2 C33H42O19 Naringinenin-4ʹ-O-glucoside-7-O-rutinoside or
Naringinenin-4ʹ-O-glucoside-7-O-neoheperidoside
F3 17 9.309 633.1410 633.1432 3.5 609.1556 609.1534 3.6 C27H30O16 6-Hydroxy kaempferol-3-O-rutinoside
*F4 18 9.429 487.0862 487.0852 2.1 463.0871 463.0877 1.3 C21H20O12 6-Hydroxy kaempferol-3-O-glucoside
FN3 19 9.779 441.1137 441.1162 5.7 417.1181 417.1186 1.2 C21H22O9 Neoliquiritin
*FN4 20 10.045 d d d 417.1186 417.1186 0.0 C21H22O9 Liquiritin
*F5 21 10.176 633.1434 633.1432 0.3 609.1461 609.1456 0.8 C27H30O16 Rutin
FN5 22 10.414 573.1589 573.1584 0.9 549.1612 549.1608 0.7 C26H30O13 Liquiritin apioside
*F6 23 10.439 d d d 463.0835 463.0877 9.1 C21H20O12 Isoquercitrin
Q2 24 10.902 616.1622 616.1642 3.2 592.1658 592.1666 1.4 C27H31NO14 Hydroxycartormin
FN6 25 11.173 473.1031 473.1060 6.1 449.1083 449.1084 0.2 C21H22O11 4ʹ,5,6,7-Tetrahydroxyl flavanone-6-O-glucoside
FN7 26 11.207 619.1642 619.1639 0.5 595.1667 595.1663 0.7 C27H32O15 Neoeriocitrin
T3 27 11.320 655.1631 655.1639 1.2 631.1666 631.1663 0.5 C30H32O15 Galloyl-paeoniflorin or isomer
T4 28 11.541 655.1624 655.1580 6.7 631.1645 631.1663 2.9 C30H32O15 Galloyl-paeoniflorin or isomer
FN8 29 11.677 595.2019 595.2027 1.3 593.1890 593.1870 3.4 C28H34O14 Neoponcirin
C1 30 11.857 676.2595 676.2605 1.5 674.2450 674.2449 0.1 C33H41NO14 Isoliquiritigenin-4-O-apiosyl-(1/2)-[2-(2-piperidyl)
acetyl]-glucoside or isomer
FN9 31 11.932 617.1864 617.1846 2.9 593.1907 593.1870 6.2 C28H34O14 Poncirin
*O3 32 12.069 647.1943 647.1952 1.4 623.1978 623.1976 0.3 C29H36O15 Verbascoside
C2 33 12.082 676.2595 676.2605 1.5 674.2424 674.2449 3.7 C33H41NO14 Isoliquiritigenin-4-O-apiosyl-(1/2)-[2-(2-piperidyl)
acetyl]-glucoside or isomer
*F7 34 12.249 471.0902 471.0903 0.2 447.0915 447.0927 2.7 C21H20O11 Astragalin
*FN10 35 12.479 603.1680 603.1690 1.7 579.1716 579.1714 0.3 C27H32O14 Narirutin
*O4 36 12.573 503.2960 503.2985 5.0 479.2997 479.3009 2.5 C27H44O7 Ecdysterone
FN11 37 12.724 457.1096 457.1111 3.3 433.1130 433.1135 1.2 C21H22O10 Naringenin-7-O-glucoside
F8 38 12.867 649.1355 649.1381 4.0 625.1417 625.1405 1.9 C27H30O17 6-Hydroxy kaempferol-di-O-glucoside
*FN12 39 13.215 603.1694 603.1690 0.7 579.1718 579.1714 0.7 C27H32O14 Naringin












































Q3 41 13.908 598.1504 598.1537 5.5 574.1539 574.1561 3.8 C27H29NO13 Cartormin
FN13 42 13.922 779.2367 779.2374 0.9 755.2375 755.2399 0.8 C34H44O19 Hesperetin-4ʹ-O-rhamnoside-7-O-rutinoside
*FN14 43 14.106 611.2001 611.1976 4.1 609.1814 609.1819 1.8 C28H34O15 Hesperidin
F10 44 14.716 609.1842 609.1819 3.8 607.1652 607.1663 1.8 C28H32O15 Diosmin or Neodiosmin
*FN15 45 14.853 611.1969 611.1976 1.1 609.1830 609.1819 0.8 C28H34O15 Neohesperidin
*FN16 46 15.108 257.0808 257.0814 2.3 255.0650 255.0657 1.8 C15H12O4 Liquiritigenin
*FN17 47 15.154 273.0793 273.0763 11.0 271.0605 271.0606 1.8 C15H12O5 Naringenin
C3 48 15.249 419.1333 419.1342 2.1 417.1176 417.1186 2.7 C21H22O9 Isoliquiritin
Q4 49 15.512 637.1505 637.1533 4.4 613.1547 613.1557 0.4 C30H30O14 Safflomin C or isomer
C4 50 15.640 615.1701 615.1690 1.8 591.1727 591.1714 2.4 C28H32O14 Acetyl-isoliquiritin apioside
FN18 51 15.644 581.1885 581.1870 2.6 579.1666 579.1714 1.6 C27H32O14 Isonaringin
T5 52 15.772 547.1685 547.1639 8.4 523.1673 523.1663 2.2 C21H32O15 Rehmannioside A
IF1 53 15.813 269.0809 269.0814 1.9 267.0656 267.0657 8.3 C16H12O4 Pallidiflorin
C5 54 15.971 441.1192 441.1162 6.8 417.1155 417.1186 1.9 C21H22O9 Neoisoliquiritin
T6 55 16.294 623.1789 623.1741 7.7 599.1720 599.1765 0.4 C30H32O13 Benzoyl-hydroxyl-paeoniflorin
C6 56 16.944 719.3814 719.3892 10.8 695.3956 695.4007 7.4 C35H36O15 Licoriceglycoside B
C7 57 17.211 749.2064 749.2058 0.8 725.2033 725.2082 7.5 C36H38O16 Licoriceglycoside A
S1 58 17.792 1277.5834 1277.5778 4.4 1253.5830 1253.5803 7.3 C58H94O29 Deapioplatycodin D3
S2 59 17.999 1409.6264 1409.6210 3.8 1385.6325 1385.6225 6.8 C63H102O33 Platycodin D2 or platycodin D3
SP1 60 18.300 584.2766 584.2761 0.9 582.2606 582.2604 2.2 C34H37N3O6 Safflospermidine A or safflospermidine B or
N1,N5,N10-(Z)-tri-p-coumaroylsperminine or
N1,N5,N10-(E)-tri-p-coumaroylsperminine
F11 61 18.382 617.1455 617.1482 4.4 593.1478 593.1506 7.2 C27H30O15 Kaempferol-3-O-rutinoside
SP2 62 18.589 584.2751 584.2761 1.7 582.2601 582.2604 0.3 C34H37N3O6 Safflospermidine A or safflospermidine B or
N1,N5,N10-(Z)-tri-p-coumaroylsperminine or
N1,N5,N10-(E)-tri-p-coumaroylsperminine
*F12 63 18.691 287.0560 287.0556 1.4 285.0403 285.0399 4.7 C15H10O6 Kaempferol
SP3 64 18.716 584.2777 584.2761 2.7 582.2598 582.2604 0.5 C34H37N3O6 Safflospermidine A or safflospermidine B or
N1,N5,N10-(Z)-tri-p-coumaroylsperminine or
N1,N5,N10-(E)-tri-p-coumaroylsperminine
S3 65 18.735 825.4304 825.4273 3.8 823.4091 823.4116 1.4 C42H64O16 Uralsaponin C or isomer
SP4 66 18.915 584.2763 584.2761 0.3 582.2600 582.2604 1.0 C34H37N3O6 Safflospermidine A or safflospermidine B or
N1,N5,N10-(Z)-tri-p-coumaroylsperminine or
N1,N5,N10-(E)-tri-p-coumaroylsperminine
S4 67 19.017 1115.5288 1115.5250 3.4 1091.5365 1091.5274 3.0 C52H84O24 Deapioplatycodin D
S5 68 19.103 1409.6280 1409.6210 5.0 1385.6316 1385.6225 0.7 C63H102O33 Platycodin D2 or Platycodin D3
*S6 69 19.195 1225.5851 1225.5853 0.2 1223.5737 1223.5697 8.3 C57H92O28 Platycodin D
S7 70 19.235 1451.6106 1451.6037 4.8 1427.6457 1427.6331 6.6 C65H104O34 2ʹʹ-O-Aceytlplatycodin D2 or
3ʹʹ-O-aceytlplatycodin D2 or isomer
T7 71 19.307 607.1791 607.1791 0.0 583.1824 583.1816 3.3 C30H32O12 Benzoyl-paeoniflorin
S8 72 19.318 1289.5876 1289.5778 7.6 1265.5905 1265.5803 8.8 C59H94O29 Platycodin A or platycodin C
S9 73 19.389 897.4158 897.4120 4.2 895.4008 895.3964 1.4 C44H64O19 22b-Acetoxy licorice saponin G2
S10 74 19.491 845.3996 845.3936 7.1 821.2969 821.2960 8.1 C42H62O16 Uralsaponin B
S11 75 19.727 1451.6464 1451.6307 10.8 1427.6309 1427.6331 4.9 C65H104O34 2ʹʹ-O-Aceytlplatycodin D2 or
3ʹʹ-O-aceytlplatycodin D2 or isomer
S12 76 19.817 1289.5904 1289.5778 9.8 1265.5800 1265.5803 1.1 C59H94O29 Platycodin A or platycodin C
S13 77 19.934 985.4635 985.4644 0.9 983.4548 983.4488 1.5 C48H72O21 Licoricesaponin A3
*C8 78 20.010 257.0815 257.0814 0.4 255.0651 255.0657 0.2 C15H12O4 Isoliquiritigenin
































































S14 79 20.201 881.4156 881.4171 1.7 879.4031 879.4014 6.1 C44H64O18 22b-Acetoxyl-glycyrrhizin or isomer
S15 80 20.509 839.4077 839.4065 1.4 837.3946 837.3909 2.4 C42H62O17 Yunganoside K2
*IF2 81 20.550 269.0808 269.0814 2.2 267.0656 267.0657 1.9 C16H12O4 Formononetin
S16 82 20.603 705.3814 705.3826 1.7 681.3857 681.3850 4.4 C36H58O12 3-O-Glucopyranosyl platycodigenin
S17 83 21.301 821.3887 821.3960 8.9 819.3806 819.3803 0.4 C42H60O16 Licorice saponin E2
*S18 84 21.347 979.4777 979.4878 10.3 955.4912 955.4903 1.0 C48H76O19 Ginsenoside-Ro
S19 85 21.411 839.4058 839.4065 0.8 837.3914 837.3909 0.4 C42H62O17 Macedonoside A
S20 86 21.745 839.4077 839.4065 1.4 837.3898 837.3909 0.9 C42H62O17 Macedonoside B
S21 87 21.824 949.5778 949.5137 67.5 925.5179 925.5161 0.6 C48H78O17 Saikosaponin C
S22 88 21.854 887.4010 887.4041 3.5 863.4072 863.4065 0.0 C44H64O17 22b-Acetoxyl-glycyrrhaldehyde
*S23 89 22.275 823.4107 823.4116 1.1 821.3956 821.3960 1.9 C42H62O16 18b-Glycyrrhizic acid
*S24 90 22.399 817.4364 817.435 1.7 793.4322 793.4374 0.8 C42H66O14 Chikusetsusaponin Iva
*F13 91 22.887 403.1385 403.1393 2.0 d d d C21H22O8 Nobiletin
S25 92 23.297 809.4266 809.4323 7.0 807.4196 807.4167 3.6 C42H64O15 22-Dehydroxy-uralsaponin C[14]
S26 93 23.465 823.4104 823.4116 1.5 821.3963 821.3960 0.4 C42H62O16 Licorice saponin H2
S27 94 23.803 979.4902 979.4878 2.5 955.4955 955.4903 5.4 C48H76O19 Yunganogenin A1/B1/C1 [24,26]
S28 95 23.822 823.4098 823.4116 2.2 821.4030 821.3960 8.5 C42H62O16 Licorice saponin K2
*S29 96 24.033 803.4545 803.4558 1.6 779.4599 779.4582 2.2 C42H68O13 Saikosaponin A
IF3 97 24.134 369.1329 369.1338 2.4 367.1172 367.1182 2.7 C21H20O6 Glisoflavone
F14 98 24.731 355.1178 355.1182 1.1 353.1008 353.1025 4.8 C20H18O6 Uralenin
F15/IF4 99 26.001 339.1218 339.1232 4.1 337.1068 337.1076 2.4 C20H18O5 Eurycarpin A or glepidotin A [7] or
6-prenyl-5,7,4ʹ-trihydroxyflavone or lupiwighteone
OF1 100 26.054 367.1131 367.1182 13.9 365.1020 365.1025 1.4 C21H18O6 Glycyrol or isoglycyrol or neoglycyrol
F16/OF2 101 30.672 425.2003 425.1964 9.2 423.1848 423.1808 9.5 C25H28O6 Gancaonin E or 3ʹ-(g,g-dimethylallyl)-kievitone
IF5 102 31.780 423.1792 423.1808 3.8 421.1644 421.1651 1.7 C25H26O6 Angustone A or isomer
OF3 103 33.641 439.2529 439.2484 10.2 437.2294 437.2328 7.8 C27H34O5 Licorisoflavan A












































j o u r n a l o f f o o d and d ru g an a l y s i s 2 3 ( 2 0 1 5 ) 8 1 1e8 2 0 819In the positive ion spectra of compound O1, the fragment
ion at m/z 120.0808 [MþHeCH2O2]þ was observed, corre-
sponding to the neutral loss of a formic acid via a rearrange-
ment specific to amino acids. By comparing the MS data,
elemental composition and fragmentation patterns with the
literature data [22], compound O1was tentatively identified as
phenylalanine. Compound O2 was definitely assigned to
amygdalin by comparison with an authentic standard. The
highest intensity product ions at m/z 323.0948
[MeHeC8H7NO]
‒ and 347.0946 [MþNaeC8H7NO]þwere formed
by the neutral loss of mandelonitrile from the parent ion.
Compound O3 exhibited a quasimolecular ion at m/z 623.1978
[MeH]e in negative ion mode. The fragment ions at m/z
461.1594 [MeHeC9H6O3]
‒ of MS/MS corresponded to a loss of
2-hydroxy-4-(3-oxoallylidene)cyclohexa-2,5-dienone. The
fragment ion atm/z 161.0222 [MeHeC20H30O12]
‒ also indicated
the presence of 2-hydroxy-4-(3-oxoallylidene)cyclohexa-2,5-
dienone. Compound O3 was identified as verbascoside by
comparison with the authentic compound. In positive ion
spectra, the adduction at m/z 647.1943 [MþNa]þ could further
support identification. Compound O4 was identified as b-
ecdysterone by comparison with authentic compound.4. Conclusion
A rapid and effective method based on UPLC-Q/TOF MS has
been developed for separation and characterization of
chemical profiles of XFZYD. This method successfully detec-
ted 103 major compounds in XFZYD, including 7 phenolic
acids, 4 spermidines, 7 terpenoids, 52 flavonoids, 29 saponins,
and 4 other compounds. The results could pave the way for
the further study of XFZYD in pharmacology andmechanism.Conflicts of interest
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